At a Glance
- Company: Tortugas Neuroscience
- Location: US
- Funding: $106M Series A
- Focus area: Neurological small molecules
- Next steps: Advance Phase I-ready assets
What happened?
Tortugas Neuroscience emerged from stealth with $106 million in Series A funding to develop a portfolio of small-molecule drugs for neurological disorders. The startup, led by former Sage Therapeutics executives, licensed candidates from Eisai and Jiangsu Hansoh Pharmaceutical Group.
Why does it matter?
Neurological diseases like depression, epilepsy and neurodegeneration represent massive unmet needs, with few new small molecules approved recently. Tortugas’ assets target validated pathways with improved profiles over first-generation therapies, potentially filling gaps left by Sage’s pipeline challenges.
Who’s behind it?
Led by Sage alumni including CEO Steve Kanes, the team brings deep experience in neurosteroids and CNS drug development. Backers include leading VCs betting on the team’s track record and the licensed assets’ clinical readiness.
How was it achieved?
The portfolio includes Phase I-ready molecules from Eisai’s GABA and ion channel programmes, plus Hansoh’s kinase inhibitors for neuroinflammation. Compounds were selected for clean safety, brain penetration and potential in treatment-resistant depression, epilepsy and beyond.
What’s next?
Tortugas will prioritise lead candidates into Phase I trials within 12 months, expand preclinical pipeline and build neuro biomarker platform. Additional partnerships with big pharma licensors expected as data emerge.